Ergomed

What Ergomed does

Ergomed plc is a United Kingdom-based clinical research organization (CRO) founded in 1997 and headquartered in Guildford. The company provides specialized services to the pharmaceutical and biotech industries through two main divisions: PrimeVigilance, which delivers post-marketing pharmacovigilance and drug safety services including adverse event reporting, signal detection, and medical information management; and Ergomed Clinical Research, which provides full-service clinical trial management, site monitoring, and regulatory support.

The company's core technology is the PrimeVigilance platform, which incorporates AI/ML-driven workflows for real-time adverse drug reaction monitoring, EHR mining, and regulatory submission support (including FDA E2B(R3) compliance). Capabilities were expanded through the acquisition of Panacea Pharma Projects Limited. The company also operates wholly owned subsidiary PrimeVigilance as a core operating unit and has built a portfolio of acquired capabilities including MedSource, Ashfield Healthcare, PSR Group, and PharmInvent.

Ergomed generates revenue through B2B professional services contracts with pharmaceutical and biotech sponsors, including large pharmaceutical companies, mid-size biotechs, and emerging biotechs. Distribution occurs via direct enterprise sales, RFP processes, and contract negotiations, supplemented by industry conference participation. Historical revenue grew from approximately $90M in 2019 to $204M in 2023, supported by M&A activity and expansion of pharmacovigilance and clinical trial services.

Name

Ergomed

Legal name

Ergomed plc

Website

https://ergomedplc.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ergomed is a UK-based clinical research organization providing pharmacovigilance and clinical trial services to pharmaceutical and biotech sponsors through its PrimeVigilance and Ergomed Clinical Research divisions.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Enterprise Risk Management (ERM) Advisory (BPAHAFAA)

Keywords

• Clinical research services
• Pharmacovigilance services
• Drug safety monitoring
• Clinical trial management
• Contract research organization

Headquarters

HQ city

Guildford

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmacovigilance services: Ergomed generates revenue through providing post-marketing pharmacovigilance services to pharmaceutical and biotech companies. This includes adverse drug reaction monitoring, signal detection, and medical information services delivered via its PrimeVigilance division.
2. Clinical trial support services: Ergomed provides clinical research organization (CRO) services including clinical trial management and operational support, as evidenced by its partnership with CEL-SCI to support trial preparations for Multikine. Services are delivered on a contract basis to pharmaceutical and biotech sponsors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Ergomed is a clinical research organization (CRO) that provides specialized pharmacovigilance and clinical trial management services to pharmaceutical and biotech sponsors. Through its PrimeVigilance division it delivers post-marketing drug safety surveillance, adverse drug reaction monitoring, signal detection, and medical information services, while its Ergomed Clinical Research division provides full-service clinical trial management, site monitoring, biostatistics, data management, and regulatory support.

Product overview

Ergomed is a specialized pharmaceutical services company operating through two main divisions: PrimeVigilance (pharmacovigilance and drug safety services) and Ergomed Clinical Research (full-service clinical trial management). The PrimeVigilance unit was expanded through the acquisition of Panacea Pharma Projects Limited, while the clinical research division provides end-to-end trial services. The company serves pharmaceutical and biotech clients with a focus on drug safety monitoring and clinical development.

Differentiator

Problem solved

Functional benefit

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered minor and core.

• OCT Europe 2026 (Arena International Events Group / GlobalData)minorGTM or Marketing Partner · 6 May 2026Ergomed Clinical Research participated as a presenter and exhibitor at the 16th Annual Outsourcing in Clinical Trials (OCT) Europe 2026 conference in Barcelona, Spain. The event brings together pharmaceutical and biotech industry leaders including GSK, Bayer, Sandoz, Alexion Pharmaceuticals, ICON, Parexel, Johnson & Johnson, and AstraZeneca. Ergomed's participation provides visibility and networking opportunities with potential pharmaceutical sponsors.
• CEL-SCI CorporationcoreStrategic or Co-development Partner · 29 December 2025Ergomed partnered with CEL-SCI Corporation to support trial preparations for the Confirmatory Registration Study of Multikine, a cancer therapy. Ergomed provided clinical research organization services including trial management and operational support. CEL-SCI reported that Ergomed was engaged to support Multikine study preparations, with patient enrollment expected in Spring 2026.
• Panacea Pharma Projects LimitedcoreStrategic or Co-development PartnerErgomed completed the acquisition of Panacea Pharma Projects Limited to expand its PrimeVigilance capabilities. The acquisition strengthens Ergomed's pharmacovigilance service offerings and broadens its ability to serve pharmaceutical sponsors with enhanced post-marketing surveillance and medical information services. Multiple market reports cite this acquisition as a key strategic development for Ergomed.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Thermo Fisher Scientific (PPD): Owns PPD, a leading global CRO offering clinical development and post-approval services including pharmacovigilance. Comparable as a broad incumbent in the same CRO market where Ergomed competes.
• IQVIA Holdings: World's largest CRO/contract commercial organization with deep clinical, real-world evidence, and safety/pharmacovigilance capabilities. Operates as a broad incumbent competing across Ergomed's full service portfolio at significantly greater scale.
• WuXi AppTec: Global CRO/CDMO with extensive clinical and safety services serving pharma/biotech, particularly strong in Asia-Pacific. Comparable to Ergomed in clinical operations and PV, and a key Asia-Pacific competitor.
• Labcorp Drug Development (formerly Covance): Major clinical CRO with global trial management and central laboratory capabilities, plus post-marketing safety services. Comparable to Ergomed across clinical operations, lab services, and pharmacovigilance.

Direct peers

• ICON plc: Global Tier-1 CRO providing full-service clinical trial management and pharmacovigilance services to pharma and biotech sponsors. Directly comparable to Ergomed across both clinical operations and PV service lines, and was a co-attendee at OCT Europe 2026.
• Syneos Health: Clinical and commercial solutions provider offering CRO services and pharmacovigilance. Comparable to Ergomed as a mid-to-large CRO serving pharma/biotech across the full clinical development lifecycle.
• Worldwide Clinical Trials: Mid-sized global CRO focused on clinical trial management across multiple therapeutic areas, with associated safety/pharmacovigilance offerings. Closely comparable in scale and service mix to Ergomed Clinical Research.
• Charles River Laboratories: Contract research organization with preclinical, clinical, and safety assessment capabilities including pharmacovigilance support. Comparable to Ergomed in serving pharma sponsors with combined safety and clinical services.
• Parexel International: Large CRO offering clinical development, pharmacovigilance, and regulatory services globally. Closely matches Ergomed's combined PV + clinical research model, and was a co-attendee at OCT Europe 2026 alongside Ergomed.

Emerging players

• Clinipace Worldwide: Mid-sized, therapeutically-focused CRO offering clinical trial management and related services to emerging biotech sponsors. Comparable in scale and mid-market sponsor focus to Ergomed Clinical Research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ErgomedPLC

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ergomed